ATTY. DOCKET NO. SERIAL NO. 09/518,098 114232.107 INFORMATION DISCLOSURE **APPLICANT** CITATION IN AN Leland SHAPIRO **APPLICATION GROUP** FILING DATE (PTO-1449) May 3, 2000 U.S. PATENT DOCUMENTS EXAMINER'S **FILING** INITIALS PATENT NO. DATE NAME **CLASS** SUBCLASS DATE AA5,175,253 12/29/92 Fallon et al. AB 5,214,191 5/25/93 Kirschenheuter et al AC 5,240,956 8/31/93 Kirschenheuter et al ΑĎ 5,281,617 1/25/94 Kirschenheuter et al ΑE 5,314,910 5/24/94 Kirschenheuter et al AF 5,416,191 5/16/95 Cheronis et al AG 5,478,727 12/26/95 Roizman et al ΑH 1)23/96 5,486,470 Darke et al, ΑI 5/7/96 5,514,653 Perlmutter AJ Goodfellow et al 3/11/97 5,610,140 ΑK 5,635,593 6/3/97 Cheronis et al ΑL Kirschenheuter et al 9/2/97 5,663,416 5,700,779 12/23/97 Goodfellow et al ΑN 1/20/98 5,710,026 Spreaher ΑO 5,712,117 1/27/98 Sprecher ΑP 5,747,645 6/6/98 Sprechen AQ Goodfellow et al 5,750,506 5/12/98 AR Bathurst/et al. 5,759,548 6/2/98 AS 5,798,442 8/25/98 Gallant et al. AT 5,811,241 9/22/98 Goodfellow et al ΑU 5,834,431 11/10/98 Stewart et al ΑV Cheronis et al 5,843,900 12/1/98 AW 12/15/98 5,849,863 Stewart et al ΑX 1/26/99 5,863,899 Cheronis et al ΑY 2/23/99 5,874,424 Batchelor et al. **DATE CONSIDERED EXAMINER** BUSIN

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFO	RM	IATION DIS	CLOSURE		ATTY. DO 114232.10	OCKET NO. 7	SERIAL N 09/518,098		_
. ve.		TATION IN APPLICATIO			APPLICAL Leland	NT SHAPIRO			
' JOHN THE		(PTO-1449)			FILING D May 3, 200		GROUP		
ADEN!			FOREIGN PA	TENT	DOCUMENT	rs .		11	j te
EXAMINER'S INITIALS		PATENT NO.	DATE	C	OUNTRY	CLASS	SUBCLASS	Transl Yes	ation
X	ВА	WO 97/03679	2/6/91	PCT	7			103	1
X	ВВ	WO98/09206	3/5/98	PCT				Abstr	
DZ	BC	WO97/09346	3/13/97	PCT	7				.,,
	BD	WO97/09347	3/13/97	PCT	3				
	BE	WO97/10222	3/20/97	PCT				<u> </u>	
	BF	WO98/06417	2/29/98	PCT					`
	BG BH	WO98/49190	11/5/98	PCT	·	 			'
	ВІ	WO00/52034	0/0/00	┼		 			-
-) (ВЈ	WO99/43308 WO94/07525	9/2/99	PCT		 		<u> </u>	
			 	┼		 	 		⊢
	-								
			<u> </u>	╁─		 	 	 	
	-		 	+			 	 	
	-			1			<u> </u>	 	\vdash
			 					†	\vdash
	\vdash		 	1		 			\vdash
			 	+		 		 	\vdash
			 	+		 		 	\vdash
	├			+-		 	 	 	┼─-

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not inconformance and not considered. Include copy of this form with next communication to Applicant.

T.				<u> </u>	1		
	PENIE	ODM	ATION DISCLOSUDE	ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098		
γÓ		PENFORMATION DISCLOSURE CITATION IN AN		APPLICANT			
	0 ' 3001 'n	ADDITION		Leland SHAPIRO	T		
YAM	JEBIC L		(PTO-1449)	FILING DATE May 3, 2000	GROUP 1653		
1/8	TRADE MET		OTHER ART (Including Author, Ti	le, Date, Pertinent Pages, Etc.)			
	DR	CA	Adelman S.F. et al., "Protease inhibite transformed cells", J Gen Virol, 1982	ors suppress fibrinolytic act	ivity of herpesvirus-		
	- CK	СВ	Altieri, D.C. J Leukoc Biol 1995, 58,				
∦	X	СС	Animal Cell Culture, R. I. Freshney, e	d., 1986			
	Aoki H, Akaike T, Abe K, Kuroda M, Arai S, Okamura R, Negi A, Maeda H. A effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex vir in vitro and in vivo. Antimicrob Agents Chemother 1995 Apr;39(4):846-9				pes simplex virus type I		
	Beal, M.F., "Mitochondria, Free Radicals, and Neurodegeneration", Curr. Opin. Neurobiol., 1996, 6, 661-666				on", Curr. Opin.		
	CF Beck, K.F. et al. in J Exp Biol 1999, 202, 653				53		
	Bjorck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol 1990 Feb;64(2):941-3						
	DX	СН					
	Bukrinskaia AG, Kitsak Vla, Moisiadi SA, Arakelov SA. Suppression of rotavirus SA-II reproduction by protease inhibitors in cell culture. Vopr Virusol 1987 Jan-Feb;32(I):71-						
		Cl Chesnokova NB, Maichuk YF. Antiproteases in herpetic keratitis. Metab Pediatr Syst Ophthalmol 1986;9(1):593-6					
	CK Chesnokova NB, Kasavina BS, Maichuk luF, Kazachenko MA, Shchipanova Al. Main proteotytic inhibitors in ocular herpes. Vopr Med Khim 1981 Sep-Oct;27(5):663-5						
1	CL Cilberto et al., 1995, Cell, 41:531-540						
	Deigner, H.P. and R. Kinscherf, "Modulating Apoptosis: Current Applications and Prospects for Future Drug Development", Curr Med Chem 1999, 6, 399-414						
		CN	Dery, 0. and Bunnett, N.W. Biochem Soc Trans 1999, 27,246-254				
) co	Dery, 0. et al. Am J Physiol 1998, 2 74, C 1429-C 1452				
	DiIanni CL, Drier DA, Deckman IC, McCann PJ 3d, Liu F, Roizinan B, Colonno RJ, Cordingley MG. Identification of the herpes simplex virus-I protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. Biol Chem 1993 Jan 25;268(3):2048-51						
	EXAMINER COULT LITTLE DATE CONSIDERED 12/4/09						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in onformance and not considered. Include copy of this form with next communication to Applicant.

PIE	DA 4	ATION DICCLOSURE	ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098			
हिंगु	CI	TATION DISCLOSURE TATION IN AN	APPLICANT Leland SHAPIRO				
AY 0. 1: 2001	P	APPLICATION (PTO-1449)	FILING DATE May 3, 2000	GROUP			
FTRADENT		OTHER ART (Including Author, Tit	le, Date, Pertinent Pages, Etc.)				
	Dilanni CL, Stevens JT, Bolgar M, O'Boyle DR 2nd, Weinheimer SP, Colonno RJ. Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. J Biol Chem 1994 Apr 29;269(17):12672-6						
DX '	CR	Ding, A. et al., in J. Immunol. 1990, 14	45, 940	,			
De	CS	Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996 Jun 15;87(12):4959-66					
DY '	Flaitz CM, Hicks MJ. "Molecular piracy: the viral link to carcinogenesis." Oral Oncol 1998 Nov;34(6):448-53						
X	Glynn JM, McElligott DL, Mosier DE. Apoptosis induced by HIV 5 infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist. J Immunol 1996 Oct 1;157(7):2754-2758						
202	CV	Goureau, 0. et al., in Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4276					
DX "	CW	Griffin, William C., "Calculation of F The Hydrophilic-Lipophilic Balance],					
, ,	СХ	Heck, D. E. et al., in J. Biol. Chem. 19	90, 267, 21277				
	CY	Holwerda BC. Herpesvirus proteases: targets for novel antiviral drugs. Antiviral Res 1997 Jun;35(1):1-21					
	cz	Jabs, Thorsten, "Reactive Oxygen Intermediates as Mediators of Programmed Cell Death in Plants and Animals", <i>Biochem Pharmacol</i> 1999 57, 231-245					
	CCA	Kaufmann, Scott H., Serge Desnoyers, Yvonne Ottaviano, Nancy E. Davidson, and Guy G. Poirier, "Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: An Early Marker of Chemotherapy-induced Apoptosis", Cancer Res 1993, 53, 3976					
V	ССВ	Kidd, Vincent .J., PROTEOLYTIC ACTIVITIES THAT MEDIATE APOPTOSIS, Annu Rev Physiol, 1998, 60, 533					
& I	ccc	Kido H, Niwa Y, Beppu Y, Towatari T. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv Enzyme Regul 1996;36:325-47					
De la	CCD	Kirkeboen, K.A. and Strand, O.A. in Acta Anaesthesiol Scand 1999, 43, 275					
XX '	CCE	Langer, R. Nature 1998, 392, 5					
X	CCF	List, P.J.M., et al., Arterioscler Thromb Vasc Biol 1999, 19, 14					
		1 100		1_/_			
EXAMINER DATE CONSIDERED 12/101							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

			 		
O STATE		IATION DISCLOSURE	ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098	
, , , , , , , , , , , , , , , , , , ,	\ Cl	ITATION IN AN	APPLICANT Leland SHAPIRO		
10 1 5000 E		APPLICATION (PTO-1449)	FILING DATE May 3, 2000	GROUP 1653	
TRACEMEN		OTHER ART (Including Author, Tit	le, Date, Pertinent Pages, Etc.)		
adod	CCG	Lomas DA, Elliott PR, Carrell RW. C contains a confornationally inactive, I Mar;10(3):672-5			
	ССН	Lowenstein, C. J. and Snyder, S.H. in	Cell 1992, 70, 705-707	1	
	CCI	Lowenstein C. J. et al. in Proc. Natl.	Acad. Sci. USA, 1993, 90	, 9730 -	
	CCI	McCall, T.B. et al., in Biochem. Bioph	ys. Res. Commun. 1992,1	86, 680	
	ССК	Meki AR, Mohey El-Dean ZM. Serun alphal-antitrypsin in scorpion enveno.			
W	CCL	Molle W. et al. in J Immunol 1997, 15	9, 3555		
DL	CCM Morel, J. B. and Dangle, J.L., Cell Death Differ 1997, 4, 67 1; Beal, M. F., Curr Opin Neurobiol 1996, 6, 661				
207	CCN	Nathan, C. in FASEB J. 1992, 6, 3051		,	
X	Novradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Tony Eissa N, Banles PM, Gabriele KM, Ehrmantraut ME, Rogliam P, Moss J. Endothelial Nitric Oxide Synthase as a Potential Susceptibility Gene in the Pathogenesis of Emphysema in alphal-Antitrypsin Deficiency. Am J Respir Cell Mol Biol 1999 Mar 1;20(3):441-447				
DL	Ooka T, Hatano Y, Yamamoto M, Ogawa K, Saika S. Protective effects of human urinary trypsin inhibitor against trypsin-induced relaxation in rat aorta. Crit Care Med 1996 Nov;24(11):1903-7				
XX	CCQ	Patel R.P., et al. in Biochim Biophys A	cta 1999,1411,385-400		
DK	Patel T, Gores GJ, Kaufmann SH. The role of proteases during apoptosis. FASEB J 1996 Apr;10(5):587-97				
X	ccs				
\sim	CCT	Popko B. and Baerwald, K. D. in Neurochem Res 1999, 24, 33 1			
De	CCU	Premack, B. A. and Schall, T. J., "Chemokine Receptors: Gateways to Inflammation and Infection", Nature Medicine, 2, 1174-1178 (1996)			
	CCV	Pryor WA, Dooley MM, Church DF. Mechanisms of cigarette smoke toxicity: the inactivation of human alpha-l-proteinase inhibitor by nitric oxide/isoprene mixtures in air. Chem Biol Interact 1985 Jul;54(2):171-83			
V	CC W	Punjabi, C. J. et al., in J. Immunol. 19	92, 149, 2179		
	CCX	Rehman A, Whiteman M, Halliwell B peroxynitrite by inhibitors and substr			
SH		Dec; 422(8) 1702-6			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

				7		
INFORMATION DISCLOSURE			ATTY, DOCKET NO. 114232,107	SERIAL NO. 09/518,098		
CITATION IN AN APPLICATION			APPLICANT Leland SHAPIRO			
	F	(PTO-1449)	FILING DATE May 3, 2000	GROUP 1653		
	80540	OTHER ART (Including Author, Ti				
X	CCY	Remington's Pharmaceutical Sciences Publishing Company, Easton, PA.		naro, A. R., ed., Mack		
X	ccz	Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.				
D.C	СВА	Schini et al. in Circ Res 1994, 74, 24		=		
DL	СВС	Sharpstone D, Rowbottom A, Nelson M, Gazzard B. Faecal alpha I antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals. Gut 1996 Feb;38(2):206-10				
DR.	CBD	Shimizu T, Pommier Y. DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies. Exp Cell Res 1996 Aug 1;226(2):292-301				
1	СВЕ	Sichko ZhV, Kozlova OL. Experience in treating a herpetic infection with trypsin [Article in Russian]. Vrach Delo 1991 Mar;(3):86-9				
	CBF	Smith, M. E. in Neurochem Res 1999, 24, 261				
X	CBG	Szeghy G, Kenyeres B. On the therapy of herpes simplex keratitis with heparin and trypsin. [Article in German] Klin Monatsbl Augenheilkd 1968;153(6):827-30				
X	СВН					
2	CBI	Wood, E.R. et al. in Biochem Biophys Res Commun 1993,191, 767-74				
×	СВЈ	Zhirnov OP, Ovcharenko AV, Mel'nikova EE, Gaidamovich Sla, Bukrinskaia AG. Antiviral activity of proteinase inhibitors in cultured cells infected with alpha-viruses. Mol Gen Mikrobiol Virusol 1985 Dec;(12):30-6				
	<u> </u>					
∦ <i> </i>	1	// /Q				
EXAMINER	Court Word 12/7/01					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not i						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DC: #181747 v1 3W8J01!.WPD 114232-107